Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. Biopharmaceutical maker Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) yesterday announced financial and ...
Streetwise Reports | August 6, 2019 |

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing

Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ) , which focuse...
Streetwise Reports | May 6, 2020 |

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |